NVO Price Prediction Next Week
Analysis and Insights
News and Market Trends:
The weight-loss drug market is experiencing rapid growth, driven by rising obesity rates and increasing demand for effective treatments. Novo Nordisk (NVO) is a key player in this market, with its GLP-1 receptor agonists, Ozempic and Wegovy, leading the charge. Recent studies indicate that global obesity rates are expected to rise significantly by 2050, further fueling demand for these drugs. Additionally, the market for next-generation obesity drugs is projected to reach $130 billion by 2030, with NVO and Eli Lilly (LLY) expected to dominate this space.
Technical Analysis:
Novo Nordisk's stock (NVO) is currently trading at $87.17, with a neutral RSI of 45.06, indicating neither overbought nor oversold conditions. The MACD is slightly bullish, with a signal line crossover, suggesting potential upward momentum. The stock is trading near its 20-day SMA ($86.20) but below its 50-day SMA ($88.59), indicating a potential sideways trend in the short term.
Fibonacci Levels:
The Fibonacci levels for NVO indicate a pivot point at $89.84, with resistance levels at $92.69 and $94.46, and support levels at $86.99 and $85.22. These levels will be critical in determining the stock's short-term movement.
Prediction and Recommendation:
Based on the bullish market trends in the weight-loss drug sector and the neutral-to-bullish technical indicators, NVO is expected to rise slightly in the next trading week. The stock is likely to test the first resistance level at $92.69, with a potential target price of $92.50.
Buy NVO at the current price of $87.17, with a target of $92.50 and a stop-loss at $85.22.
NVO Similar Chart Price Prediction
The price of NVO is predicted to go up -6.45%, based on the high correlation periods with PSTV. The similarity of these two price pattern on the periods is 93.26%.
NVO
PSTV
Down: -6.45%Similarity: 93.26%
NVO Stock Forecast & Prediction For Years 2025, 2026, 2027, 2028, 2029 and 2030
Year
NVO Price Forecast($)
Potential Return(%)
2025
87.250
-0.460
2026
120.000
32.380
2027
140.000
54.440
2028
180.000
98.570
2029
173.470
91.360
2030
150.000
65.470
What is NVO stock price prediction 2025 ?
What is NVO stock price prediction 2026 ?
What is NVO stock price prediction 2027 ?
What is NVO stock price prediction 2028 ?
What is NVO stock price prediction 2029 ?
What is NVO stock price prediction 2030 ?
NVO Revenue Forecast
NVO EPS Forecast
NVO FAQs
What is NVO revenue forecast for next quarter？
NVO VS S&P500
Novo's new obesity therapy Wegovy is significantly expanding the obesity treatment market given its strong efficacy and is poised to remain a key drug in the market until patent expiration in 2032.
With a solid portfolio of GLP-1 products, including injectable Ozempic and oral Rybelsus, Novo is well positioned to defend its formidable diabetes market share.
Semaglutide is also being studied in areas including liver disease (NASH) and Alzheimer's, and Novo could achieve a strong share in these nascent markets.
NVO Analyst's Forecast
Jo Walton
UBS
Strong Sell → Strong Buy
2025-01-08
Price Target
n/a
Downside
0%
UBS analyst upgraded Novo Nordisk to Buy from Neutral with a price target of DKK 750, down from DKK 1,100. Novo Nordisk is "well placed" to continue to benefit from the high demand for GLP-1 medications in the near-term, and while the CagriSema Phase 3 data in obesity was disappointing, it is still a higher efficacy treatment that could still show differentiation in type 2 diabetes. UBS is a buyer of weakness and says shares are at an attractive entry point following the "overdone" selloff.
Evan David Seigerman
BMO Capital
Buy
2024-12-23
Price Target
$156 → $105
Upside
+20.18%
Evan David Seigerman
BMO Capital
Buy
2024-10-17
Price Target
$160 → $156
Upside
+31.93%
